Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellSource CoTSE:4880 69 EV-to-EBITDA is 5.33 as of Aug. 28, 2026, which is 86% below its 10-year median of 37.80. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円777.22 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 414 Biotechnology companies, CellSource Co ranks better than 68.36% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CellSource Co's enterprise value is 円2,046 Mil.
CellSource Co's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was 円384 Mil. Therefore, CellSource Co's EV-to-EBITDA for today is 5.33.
The historical rank and industry rank for CellSource Co's EV-to-EBITDA or its related term are showing as below:
TSE:4880'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.23 Med: 37.8 Max: 283.75
Current: 5.34
During the past 9 years, the highest EV-to-EBITDA of CellSource Co was 283.75. The lowest was 4.23. And the median was 37.80.
TSE:4880's EV-to-EBITDA is ranked better than 68.36% of 414
companies
in the Biotechnology industry
Industry Median: 13.55
vs TSE:4880: 5.34
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CellSource Co's PE Ratio (TTM) for today is calculated as:
CellSource Co's share price for today is 円343.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CellSource Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 was 円3.560.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for CellSource Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4880 vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, CellSource Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CellSource Co's EV-to-EBITDA falls into.
CellSource Co's current Enterprise Value is 円2,046 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CellSource Co's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was 円384 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellSource Co (TSE:4880) has a EV-to-EBITDA of 5.33 as of Aug. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CellSource Co. This is 86% below median its historical median of 37.80. Over the past decade, CellSource Co's EV-to-EBITDA has ranged from 4.23 to 283.75. According to the industry distribution chart, CellSource Co ranks #131 out of 414 companies in the Biotechnology industry, placing it in the top 31.6%.
Is CellSource Co's EV-to-EBITDA too high?
CellSource Co's current EV-to-EBITDA of 5.33 is 86% below median its 10-year median of 37.80. Over the past 10 years, this metric has ranged from a low of 4.23 to a high of 283.75. The Biotechnology industry median EV-to-EBITDA is 13.55. CellSource Co's value of 5.33 is 60.7% below this industry median. Based on the distribution chart, CellSource Co ranks #131 out of 414 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #131 out of 414 companies for EV-to-EBITDA. This puts CellSource Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.55. CellSource Co's value of 5.33 is 60.7% below this benchmark. Historically, CellSource Co's own EV-to-EBITDA has ranged from 4.23 to 283.75 over the past decade. While the company's 10-year median is 37.80 vs. the industry median of 13.55, CellSource Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.55, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellSource Co's current EV-to-EBITDA of 5.33 is 60.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CellSource Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellSource Co's current EV-to-EBITDA is 5.33, which is 86% below median its own 10-year median of 37.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円777.22, compared to a current price of 円343.00 — trading 55.9% below its estimated fair value. The current EV-to-EBITDA is 5.33, which is 86% below median its 10-year median of 37.80 and 60.7% below the Biotechnology industry median of 13.55. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current EV-to-EBITDA is 5.33 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円343.00 is trading 55.9% below its estimated GF Value™ of 円777.22.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
EV-to-EBITDA: 5.33 (86% below median its 10-year median of 37.80)
GF Value™: 円777.22 vs. price of 円343.00 (55.9% below fair value)
Industry Position: 60.7% below the Biotechnology median (#131 of 414)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score
Get the complete analysis for TSE:4880
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
